Show results for
Refine by
Immunotherapy Suppliers Serving Nigeria
89 companies found
based inNanjing, CHINA
Founded in 2013, Frontier Biotechnologies Inc. (“Frontier Biotech”) is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness. Frontier Biotech is committed to discovering, development, ...
Licensed with exclusive rights for greater China from AFFiRiS AG, a clinical-stage biotechnology company in Austria, FB6001 is an investigational therapeutic peptide vaccine targeting PCSK9 to treat hypercholesterolemia. PCSK9 is a clinically ...
based inHamburg, GERMANY
Revvity Gene Delivery (formerly SIRION Biotech) supports your cell and gene therapy development process ̶ offering solutions for early R&D all the way to clinical applications, with easy transfer of processes and assays into GMP production. ...
based inNotting Hill, AUSTRALIA
Cartherics is developing its novel “off-the-shelf” (allogeneic) immune therapy products for the treatment of cancer based on immune killer cells. The company is developing large-scale manufacture of these CAR-iNK cells for application in human ...
based inAlameda, CALIFORNIA (USA)
Since its inception in 1998, AllCells, a Discovery Life Sciences Company, has focused on advancing science in an innovative, collaborative, and client-centric manner. In our corporate video, AllCells’ Founder, Jay Tong, describes his early days in ...
based inDuisburg, GERMANY
Genekam Biotechnology AG was found in 1999. It started offering DNA-Tests in 2001. From 2004, it started development of PCR kits while exporting to 5 countries, today (2015) it exports to 70 countries in the world. Genekam covers different targets ...
There are many laboratories developing CAR T-cell therapies. Genekam has a number of kits to develop CAR T-Cell therapy e.g. isolate large number of T cells (CD4 / CD8) from blood or other source. This isolation kit will generate larger number of ...
based inStockholm, SWEDEN
Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development. We develop two novel disease-modifying drugs: the antigenspecific immunotherapy Diamyd and the oral regenerative and immunomodulatory therapeutic ...
Diamyd® is a suspension for injection containing the active pharmaceutical ingredient GAD65 mixed with the vaccine adjuvant Alhydrogel (alum). The human recombinant protein GAD65 is manufactured in insect cells in a well-controlled GMP process. ...
based inGroningen, NETHERLANDS
ViciniVax is a Dutch clinical stage biopharmaceutical company. It is a spin-off from the University Medical Center Groningen, the Netherlands, developing therapeutic cancer vaccines. Our first product candidate Vvax001, a therapeutic cancer vaccine ...
Our first product candidate Vvax001, a therapeutic cancer vaccine against (pre)malignant cervical lesions, is currently in clinical development. We outsource process development and GMP manufacturing to experienced CMO’s, leading to a first ...
based inGosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
based inAddison, TEXAS (USA)
VITRUVIAN BioMedical, Inc is a biotechnology company focused on a unique Business Strategy based on Early, Medium and Late Stage product development. We are committed to providing 'Advance Personalized Medicine' to medical professionals and patients ...
VITRUVIAN has obtained the Exclusive Global License for a Therapeutic Vaccine for the Prevention of Alzheimer's Disease. YM7555 - Alzheimer’s Disease Therapeutic Vaccine targeting ABeta and TAU. VITRUVIAN has received an Exclusive Global ...
based inOslo, NORWAY
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer ...
NEC OncoImmunity AS has developed an AI engine for its clinical projects, known as the NEC Immune Profiler, that predicts from next generation sequencing data true neoantigens for personalized cancer immunotherapy and cancer ...
based inCounty of New Castle, DELAWARE (USA)
MedGenome Inc. is a global leader in personalized medicine with unique genomic solutions in immuno-oncology, diabetes, ophthalmology, cardiology and other rare diseases. Founded in 2013, MedGenome currently has a Next Generation Sequencing (NGS) ...
Profiling the Tumor Microenvironment: Using a genomics based approach to analyze the tumor microenvironment can provide unique insights beyond IHC and FACS methods. OncoPeptTUME deeply interrogates RNA-Seq data sets to produce high resolution ...
based inFremont, CALIFORNIA (USA)
BioGenex designs, develops and commercializes molecular pathology systems for Tumor diagnosis, prognosis, precision medicine and life science research. BioGenex’s industry-leading next-generation cytogenetic FISH workflow solution and miRNA system ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid ...
based inMinneapolis, MINNESOTA (USA)
Bio-Techne empowers researchers in Life Science and Clinical Diagnostics by providing high-quality reagents, instruments, custom manufacturing, and testing services. Our family of brands creates a unique portfolio of products and services. Science ...
Immune cell therapy is rapidly emerging as an important alternative for cancer treatment, as well as treatment of autoimmune disease. Also known as adoptive cell therapy or cellular immunotherapy, it supercharges an ...
based inSan Diego, CALIFORNIA (USA)
Decipher, a part of Veracyte, offers genomic tests for urologic cancers. Decipher Biosciences offers a portfolio of genomic tests, continues to build the GRID database of over 70,000 whole transcriptome profiles, and is partnering with ...
Nearly a decade of research and clinical testing has resulted in the accumulation of more than 85,000 whole transcriptome tumor profiles. Decipher GRID (for Research Use Only) is a proprietary artificial intelligence platform and database generating ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
Our clinically validated T-SIGn® viral vector platform delivers multiple transgene payloads that re-program the tumor microenvironment of both primary and metastatic tumors. Our platform can integrate rationally designed synthetic agents to ...
based inDallas, TEXAS (USA)
Lupagen is a privately held early stage biotech company developing first-in-class bedside enabled cell & gene therapies (CAR-T cell, gene editing and immunotherapy products) based on their patent-pending bedside point-of-care C and GT production and ...
based inShanghai, CHINA
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...
ES002’s dual ATP-adenosine mechanism is a potentially powerful TME regulator and transformative cancer immunotherapy. In preclinical studies ES002 demonstrated significant single agent anti-tumor activity as well as an ...
based inSeoul, SOUTH KOREA
We make software that transforms medical data into deeper insight. Our AI technology takes medical intelligence to the next level: data-driven medicine. We aim to solve the most critical issues in cancer care today: reduce medical cost and prolong ...
Quantifying PD-L1 positivity with AI analysis; Finding more PD-L1 positive patients; Counting every PD-L1 positive tumor cell; Complex is what AI does ...
based inLachen, SWITZERLAND
We are the largest privately owned and independent plasma fractionator in the world. Family-owned since being established in 1983, Octapharma is a global healthcare company headquartered in Lachen, Switzerland. Our products are available in 118 ...
octagam® 5% (50 mg/ml), Human Normal Immunoglobulin. octagam® 10% (100 mg/ml), Human Normal Immunoglobulin. Liquid, ready-to-use intravenous immunoglobulin ...